米国市場銘柄情報

PALI パリセード・バイオ

銘柄追加

7.7400
+0.4500+6.17%

終値 05/03 16:00 ET

7.3000
-0.4400-5.68%

市場後 19:59 ET

658.98万時価総額-286直近PER

パリセード・バイオに関するコメント

ログインコメントを投稿

Kevin Matte

03/10 09:34

Bullish on this

$パリセード・バイオ(PALI.US)$
Positive divergence for RSI and MACD ^^
Volume seem getting bigger !

Mcsnacks H Tupack

01/31 16:59

It's primed

$Wang & Lee Group(WLGS.US)$ Ready to make its big move. Resistance is at .87 then it runs. 🤞🏽
$Spectral AI(MDAI.US)$ Has had big spreads the last few days. Still trying to breakout at 3.70. No shares available.
Stocks looking for a small recovery with no shares:
$Digital World Acquisition Corp(DWAC.US)$
$ブルフロッグAIホールディングス(BFRG.US)$
$パリセード・バイオ(PALI.US)$
My Monday stocks on pace still:
$Haoxi Health Technology(HAO.US)$ Reached 8.03
$SU Group Holdings(SUGP.US)$ Moved sideways Monday and...

Ninjago7211

01/30 05:12

$パリセード・バイオ(PALI.US)$ set my sell at 1.50 around 9.15am, missed by a penny so i held thinking it would make some type of rebound..NOPE it flat linned and i there was nobody around with paddles to bring it back to life. Question is Now What?

Moo Top

2023/12/28 21:07

Pump and dump...

$パリセード・バイオ(PALI.US)$ Keep watch for any bounce...

102914606

2023/09/07 19:01

$パリセード・バイオ(PALI.US)$ There's only 35k shares balance for borrowing at 186%. If there's any short activities for this stock, it would be those holding the shares. Furthermore, the rise yesterday is < $1. It basically not worth to short it unless they push up further.Thi is my own opinion.

Yuanhunglo

2023/09/07 02:59

$Palisade Bio (PALI.US)$ wtf??? I closed my position and took am L one week ago because there was no recovery in sight... Hindsight's 20/20. I had been holding since Feb & was up ~$10 before their hard crash. Dam! 🫣😶‍🌫️

Alvinnnnnnngenius

2023/09/06 23:33

Luckily I took my profit to Nbse

$オール・ファーマシューティカル(NBSE.US)$
$パリセード・バイオ(PALI.US)$ im not bullish on this for longer term , just quick profit from 0.81 to 1.7

Trytosaveabit

2023/09/06 21:01

News!

$パリセード・バイオ(PALI.US)$ Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease